Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.

•SOF/VEL/VOX demonstrated excellent effectiveness in patients with HCV and previous DAA failure in a real-life study.•Cirrhosis (p = 0.005) and hepatocellular carcinoma onset (p = 0.02) were the only features associated with treatment failure.•Treatment failures (4%) occurred in patients with cirrhosis, with genotypes HCV-1a and 3 the most represented.